Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology ...

Milestone will present a moderated poster presentation at the American College of Cardiology annual meeting, to be held March 29th to 31st, ...

Abstracts and additional details can be found at the SIRS 2025 website.

(4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on ...